1McGrath, J, Saha, S, Chant, D, Welham, J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30(1): 67–76.
2Charlson, FJ, Ferrari, AJ, Santomauro, DF, Diminic, S, Stockings, E, Scott, JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull 2018; 44(6): 1195–203.
3Lally, J, Maccabe, JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull 2015; 114: 169–79.
4Howes, OD, McCutcheon, R, Agid, O, de Bartolomeis, A, van Beveren, NJM, Birnbaum, ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017; 174(3): 216–29.
5Horsdal, HT, Wimberley, T, Köhler-Forsberg, O, Baandrup, L, Gasse, C. Association between global functioning at first schizophrenia diagnosis and treatment resistance. Early Interv Psychiatry 2018; 12(6): 1198–202.
6Gudeman, JE, Shore, MF. Beyond deinstitutionalization, a new class of facilities for the mentally ill. N Engl J Med 1984; 311(13): 832–6.
8Ker, S, Anderson, I. Service innovations: developing a specialised (tertiary) service for the treatment of affective disorders. Psychiatr Bull 2006; 30: 103–5.
9Wasylenki, D, Goering, P, Cochrane, J, Durbin, J, Rogers, J, Prendergast, P. Tertiary mental health services: I. Key concepts. Can J Psychiatry 2000; 45: 179–84.
10Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Örey, D, Richter, F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951–62.
11Siskind, D, Reddel, T, MacCabe, JH, Kisely, S. The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study. Psychopharmacology 2019; 236(6): 1931–5.
12Cho, J, Hayes, RD, Jewell, A, Kadra, G, Shetty, H, MacCabe, JH, et al. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta Psychiatr Scand 2019; 139(3): 237–47.
13Wimberley, T, MacCabe, JH, Laursen, TM, Sørensen, HJ, Astrup, A, Horsdal, HT, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 2017; 174(10): 990–8.
14Patchan, K, Vyas, G, Hackman, AL, Mackowick, M, Richardson, CM, Love, RC, et al. Clozapine in reducing aggression and violence in forensic populations. Psychiatr Q 2018; 89(1): 157–68.
15Bhavsar, V, Kosidou, K, Orsini, N, Widman, L, Maccabe, J, Dalman, C. Could clozapine reduce violent offending? Schizophr Bull 2018; 44: S67.
16Volavka, J. Aggression and substance abuse in schizophrenic patients. Psychiatry 1999; 60(suppl 12): 43–6.
17Stroup, TS, Lieberman, JA, McEvoy, JP, Davis, SM, Swartz, MS, Keefe, RS, et al. CATIE Investigators. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009; 107(1): 1–12.
18Thompson, JV, Clark, JM, Legge, SE, Kadra, G, Downs, J, Walters, JTR, et al. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. J Psychopharmacol 2016; 30(5): 436–43.
19Dold, M, Leucht, S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health 2014; 17(2): 33–7.
20Kadra, G, Stewart, R, Shetty, H, MacCabe, JH, Chang, CK, Kesserwani, J, et al. Antipsychotic polypharmacy prescribing and risk of hospital readmission. Psychopharmacology 2018; 235(1): 281–9.
21Perera, G, Broadbent, M, Callard, F, Chang, CK, Downs, J, Dutta, R, et al. Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) case register: current status and recent enhancement of an electronic mental health record-derived data resource. BMJ Open 2016; 6(3): e008721.
22Krivoy, A, Joyce, D, Tracy, D, Gaughran, F, MacCabe, J, Lally, J, et al. Real-world outcomes in the management of refractory psychosis. J Clin Psychiatry 2019; 80(5): 18m12716.
23Sarkar, SN, Tracy, DK, Fernandez, MJ, Nalesnik, N, Dhillon, G, Onwumere, J, et al. Unheard voices: outcomes of tertiary care for treatment-refractory psychosis. Psychiatr Bull 2014; 38(2): 71–4.
24Joint Formulary Committee. British National Formulary (76th ed). BMJ Group and Pharmaceutical Press, 2018.
25Shepard, DJ, Insole, LM, McAllister-Williams, RH, Nicole, FI. Are specialised affective disorder services useful? Psychiatr Bull 2009; 33: 41–3.
26Ker, S, Anderson, I. Service innovations: developing a specialised (tertiary) service for the treatment of affective disorders. Psychiatr Bull 2006; 30: 103–5.
27Brodaty, H, Harris, L, Wilhelm, K, Hickie, I, Boyce, P, Mitchell, P, et al. Lessons from a mood disorders unit. Aust N Z J Psychiatry 1993; 27(2): 254–63.
29Kingsmore, D, Hole, D, Gillis, C. Why does specialist treatment of breast cancer improve survival? The role of surgical management. Br J Cancer 2004; 90: 1920–5.
30Ismail, F, Mitchell, L, Casabonne, D, Gulati, A, Newton, R, Proby, CM, et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Br J Dermatol 2006; 155(5): 916–25.
31Bird, GT, Farquhar-Smith, P, Wigmore, T, Potter, M, Gruber, PC. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. Br J Anaesth 2012; 108(3): 452–9.
32Majeed, A, Allwood, D, Foley, K, Bindman, A. Healthcare outcomes and quality in the NHS: how do we compare and how might the NHS improve? BMJ 2018; 362: k3036.
33Tracy, DK, Joyce, DW, Sarkar, SN, Fernandez, MM, Shergill, SS. Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia. BMC Psychiatry 2015; 15: 174.
34Agid, O, Arenovich, T, Sajeev, G, Zipursky, RB, Kapur, S, Foussias, G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011; 72(11): 1439–44.
35Daod, E, Krivoy, A, Shoval, G, Zubedat, S, Lally, J, Vadas, L, et al. Psychiatrists’ attitude towards the use of clozapine in the treatment of refractory schizophrenia: a nationwide survey. Psychiatry Res 2019; 275: 155–61.
36Office for National Statistics. National Records of Scotland; Northern Ireland Statistics and Research Agency (2016): 2011 Census aggregate data. UK Data Service (Edition: June 2016). ONS, June 2016 (http://doi.org/10.5257/census/aggregate-2011-1).
37Fearon, P, Kirkbride, J, Morgan, C, et al. Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP study. Psychol Med 2006; 36(11): 1541–50.
38Barnett, P, Mackay, E, Matthews, H, Gate, R, Greenwood, H, Ariyo, K, et al. Ethnic variations in compulsory detention under the Mental Health Act: a systematic review and meta-analysis of international data. Lancet Psychiatry 2019; 6(4): 305–17.
40Onwumere, J, Jansen, JE, Kuipers, E. Editorial: family interventions in psychosis change outcomes in early intervention settings – how much does the evidence support this? Front Psychol 2018; 9: 406.